Results 61 to 70 of about 411,261 (379)
Biochemical Pharmacology, 2015 Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994 to first approval in 2003. Bortezomib is a reversible boronic acid inhibitor of the chymotrypsin-like activity of the proteasome ...
Teicher, Beverly A. +1 more
openaire +2 more sources
The IQ‐compete assay for measuring mitochondrial protein import efficiencies in living yeast cells
FEBS Letters, EarlyView.The efficiency of mitochondrial protein import depends on the properties of the newly synthesized precursor proteins. The Import and de‐Quenching Competition (IQ‐compete) assay is a novel method to monitor the import efficiency of different proteins by fluorescence in living yeast cells.
Yasmin Hoffman +3 more
wiley +1 more source
Dynamic Regulation of the 26S Proteasome: From Synthesis to Degradation
Frontiers in Molecular Biosciences, 2019 All eukaryotes rely on selective proteolysis to control the abundance of key regulatory proteins and maintain a healthy and properly functioning proteome.
R. S. Marshall, R. Vierstra
semanticscholar +1 more source
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications [PDF]
, 2012 Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes.
Fulda, Simone +2 more
core +1 more source
Order of the Proteasomal ATPases and Eukaryotic Proteasome Assembly [PDF]
Cell Biochemistry and Biophysics, 2011 The 26S proteasome is responsible for a large fraction of the regulated protein degradation in eukaryotic cells. The enzyme complex is composed of a 20S proteolytic core particle (CP) capped on one or both ends with a 19S regulatory particle (RP). The RP recognizes and unfolds substrates and translocates them into the CP.
Robert J, Tomko, Mark, Hochstrasser
openaire +2 more sources
FEBS Letters, EarlyView.PARP‐1 is a key enzyme in the DNA damage response, and its inhibition induces cancer cell death via synthetic lethality. Au(I)‐based drugs, such as aurothioglucose and sodium aurothiomalate, block PARP‐1's DNA‐dependent activity by targeting its zinc finger domains.
Uliana Bashtanova, Melinda Jane Duer
wiley +1 more source
Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome
Nature Communications, 2018 Artemisinin and its derivatives (collectively referred to as ARTs) rapidly reduce the parasite burden in Plasmodium falciparum infections, and antimalarial control is highly dependent on ART combination therapies (ACTs).
Jessica L. Bridgford +11 more
semanticscholar +1 more source
The proteasome lid triggers COP9 signalosome activity during the transition of Saccharomyces cerevisiae cells into quiescence. [PDF]
, 2019 The class of Cullin–RING E3 ligases (CRLs) selectively ubiquitinate a large portion of proteins targeted for proteolysis by the 26S proteasome. Before degradation, ubiquitin molecules are removed from their conjugated proteins by deubiquitinating enzymes,
Bramasole, Lylan +8 more
core
The role of histone modifications in transcription regulation upon DNA damage
FEBS Letters, EarlyView.This review discusses the critical role of histone modifications in regulating gene expression during the DNA damage response (DDR). By modulating chromatin structure and recruiting repair factors, these post‐translational modifications fine‐tune transcriptional programmes to maintain genomic stability.
Angelina Job Kolady, Siyao Wang
wiley +1 more source
Insulin/IGF-1 Signaling Regulates Proteasome Activity through the Deubiquitinating Enzyme UBH-4
Cell Reports, 2013 The proteasome plays an important role in proteostasis by carrying out controlled protein degradation in the cell. Impairments in proteasome function are associated with severe and often age-related diseases.
Olli Matilainen +4 more
doaj +1 more source